QA - jastro.or.jp

1 I QA LDR 1 2 3 4 5 6 7 8 9 10 HDR 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 LDR 1 2 3 4 5 6 7 8 9 ii 10 11 12 13 14 HDR 1 2 3 4 5 6 7 8 9 10 11 A 1 2 3 4 5 6 7 8 9 B 1 2 3 4 5 LDR QA 1 2 QA HDR QA 1 2 3 4 5 6 7 iii PTV CTV JASTRO QA QA 2002 10 Image-Guided Brachytherapy 125I JASTRO QA 2013 3 15 iv -90 -106 -125 -137 -192 -198 (The American Association of Physicists in Medicine)

2 (American College of Radiology) (American Society for Therapeutic Radiation Oncology) (Biological Effective Dose) (Computed Tomography) (Clinical Target Volume) (Dose Volume Histogram) (European Society for Therapeutic Radiology and Oncology) (Field Of View) (The Groupe Europ en de Curieth rapie) (Gross Tumor Volume) (High Dose Rate) (International Commission on Radiation Units and measurements) (Image Guided BrachyTherapy) (Intensity Modulated Radiation Therapy) (International Prostate Symptom Score) (Japanese Society for Therapeutic Radiology and Oncology) (Japan Radiological Society) (Japan Society of Medical Physics) (The Japanese Urological Association) (Low Dose Rate) (Luteinizing Hormone Releasing Hormone) (Magnetic Resonance Imaging) (Positron Emission Tomography) (Personal Computer) (Patient Controlled Analgesia) (Prostate Specific Antigen) (Planning Target Volume) (Quality Assurance) (Quality Of Life) 90Sr 106Ru 125I 137Cs 192Ir 198Au AAPM ACR ASTRO BED CT CTV DVH ESTRO FOV GEC GTV HDR ICRU IGBT IMRT IPSS JASTRO JRS JSMP JUA LDR LHRH MRI PET PC PCA PSA PTV QA QOL v (Remote AfterLoading System) (Randomized Controlled Trial) (Radiology Information System)

3 NHT 125 AHT NHT 125 (Study of Seed and Hormone for Intermediate-risk Prostate Cancer) 43 (Update of Task Group No. 43 Report) TG-43U1 (Supplement of Update of Task Group No. 43 Report) (RTC of TRI-Modalities with I-125 Brachytherapy and EBRT and Short or Long term Hormone Therapy for High-risk Localized Prostate Cancer) (Trans Rectal Ultra Sound) RALS RCT RIS SHIP TG-43U1 TG-43U1S1 TRIP TRUS 6 LDR LDR 1) 1 T1-T2 T3 2 3 N0 2) T1-T23, 4) T3 5)

4 10-15 mm 7 4 137Cs 192Ir 740 MBq 370 MBq 6, 7) 198Au 185 MBq 198Au 8) 5 GTV MRI PET/CT CTV GTV + 5-10 mm PTV CTV 137Cs 198Au Paterson & Parker 192Ir Paris Paterson & Parker 137Cs 198Au Paterson & Parker 137Cs 5 mm 60-70 Gy 5-7 198Au 5 mm 80-90 Gy 192Ir Paris Paterson & Parker Paris 60-70 Gy Paterson & Parker 5 mm 60-70 Gy 5-7 6 198Au 8 137Cs 137Cs X 192Ir Guide Gutter 192Ir 198Au

5 5 mm 137Cs 192Ir 7 + Level I-II 5-10 mm CTV 5-10 mm PTV 30-50 Gy / 15-25 30 Gy + 50 Gy 40-45 Gy + 25-30 Gy 9 8 137Cs 192Ir X 2 X PTV 200% CT CT 198Au X 9 2 1 1 5 2 10 137Cs 192Ir 198Au 3 LDR HDR 10 1.

6 Mazeron JJ, Ardiet JM, Haie-M der C, et al: GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 91: 150-156, 2009. 2. , , , : . JOHNS 20: 225-229, 2004. 3. Shibuya H, Hoshina M, Takeda M, et al: Brachytherapy for stage I & II oral tongue cancer: an analysis of past cases focusing on control and complications. Int J Radiat Oncol Biol Phys 26: 51-58, 1993. 4. Fujita M, Hirokawa Y, Kashiwado K, et al: Interstitial brachytherapy for stage I and II squamous cell carcinoma of the oral tongue: factors influencing local control and soft tissue complications. Int J Radiat Oncol Biol Phys 44: 767-775, 1999. 5. Ihara N, Shibuya H, Yoshimura R, et al: Interstitial brachytherapy and neck dissection for stage III squamous cell carcinoma of the mobile tongue.

7 Acta Oncol 44: 709-716, 2005. 6. Shibuya H, Takeda M, Matsumoto S, et al: Brachytherapy for non-metastatic squamous cell carcinoma of the buccal mucosa. Acta Oncol 32: 327-330, 1993. 7. Matsumoto S, Takeda M, Shibuya H, et al: T1 and T2 squamous cell carcinomas of the floor of the mouth: results of brachytherapy mainly using 198Au grains. Int J Radiat Biol Phys 34: 833-841, 1996. 8. Takeda M, Shibuya H, Inoue T: The efficacy of gold-198 grain mold therapy for mucosal carcinomas of the oral cavity. Acta Oncol 35: 463-467, 1996. 11 HDR LDR RALS HDR 1-6) HDR 1) HDR LDR 1 T1-T2 T3 2 3 N0 T1-T2 T3 10-15 mm 4 RALS 192Ir 12 5 GTV MRI PET/CT CTV GTV + 5-10 mm PTV CTV Paris Paterson & Parker Paris 85% 54 Gy / 9 / 5-7 60 Gy / 10 / 5-7 2)

8 Paterson & Parker 5 mm 6 1 cm 3) 13 7 + Level I-II 40 Gy / 20 30 Gy / 15 HDR 48 Gy / 8 4) 8 7) 8 2 X CT PTV 200% 9 6 10 2 1 1 5 1-2 2 - 11 5) 6, 8) 3 mm 14 1.

9 , , , : . , , , 2002, pp49-62. 2. Inoue T, Inoue T, Yoshida K, et al: Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer. Int J Radiat Oncol Biol Phys 51: 171-175, 2001. 3. , , , : . 37: 1121-1124, 1992. 4. Kakimoto N, Inoue T, Inoue T, et al: Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. Radiother Oncol 68: 123-128, 2003. 5. Inoue T, Inoue T, Yamazaki H, et al: High dose rate versus low dose rate interstitial radiotherapy for carcinoma of the floor of mouth. Int J Radiat Oncol Biol Phys 41: 53-58, 1998. 6. Nose T, Koizumi M and Nishiyama K: High-dose-rate interstitial brachytherapy for oropharyngeal carcinoma: results of 83 lesions in 82 patients.

10 Int J Radiat Oncol Biol Phys 59: 983-991, 2004. 7. Mazeron JJ, Ardiet JM, Haie-M der C, et al: GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 91: 150-156, 2009. 8. Nag S, Cano ER, Demanes DJ, et al: The American Brachytherapy Society Recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 50: 1190-1198, 2001. 15 LDR RALS HDR RCT LDR HDR 1-6) 3 1 IA2-IVA 2 3 IA2 IB 4 RALS 192Ir 60Co 2 X 5 JASTRO 2012 3) / / MRI T2 IB2 IIA2 16 2011 4)